Skip to main content

Table 2 Current recruiting and non-recruiting clinical trials of mucins

From: Comprehensive analysis of the mechanism and treatment significance of Mucins in lung cancer

Drug Name

Clinical trial ID

Phase

Clinical trial

TG4010+ chemotherapy

NCT00415818

Phase 2/3

A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010(MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non-Small Cell Lung Cancer

TG4010 + placebo

NCT01383148

Phase 2/3

A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy with or Without TG4010 Immunotherapy Product in Patients with Stage IV NSCLC

TG4010 + Nivolumab

NCT02823990

Phase 2

Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients with Metastatic NSCLC

TG4010 + Nivolumab

NCT03353675

Phase 2

A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined with TG4010 and Nivolumab in Patients with Advanced Non-squamous NSCLC

Tecemotide (L-BLP25)

NCT00157196

Phase 2

A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in NSCLC Patients with Unresectable Stage III Disease

Tecemotide (L-BLP25)

NCT00157209

Phase 2

A Multicenter Phase IIb Randomised, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of NSCLC

Tecemotide

NCT00409188

Phase 3

A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in NSCLC Subjects with Unresectable Stage III Disease.

Tecemotide (L-BLP25)

NCT01015443

Phase 3

A Multi-national, Double-blind, Placebo-controlled, Randomized, Phase III Clinical Trial of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Asian Subjects with Stage III, Unresectable, NSCLC Who Have Demonstrated Either Stable Disease or Objective Response Following Primary Chemo-radiotherapy

Tecemotide

NCT02049151

Phase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects with Completed Concurrent Chemo-radiotherapy for Unresectable Stage III NSCLC

Tecemotide

NCT00960115

Phase 1/2

Combined Phase I/II Clinical Study of EMD531444(L-BLP25 or BLP25 Liposome Vaccine) in Subjects with Stage III Unresectable Non-Small Cell Lung Cancer Following Primary Chemoradiotherapy

Tecemotide+Bevacizumab

NCT00828009

Phase 2

A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation

Tecemotide

NCT01423760

Not Applicable

An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials

ETBX-051+ ETBX-061+ ETBX-011

NCT02140996

Phase 1

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People with Advanced Cancer

anti-MUC1 CAR T cells

NCT03525782

Phase 1/2

A Clinical Study of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Patients with Advanced Non-small Cell Lung Cancer

anti-MUC1 CAR-pNK cells

NCT02839954

Phase 1/2

Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor-Modified pNK Cells in MUC1 Positive Advanced Refractory or Relapsed Solid Tumor

anti-MUC1 CAR T cells

NCT02587689

Phase 1/2

Phase I/II Study of Anti-MUC1 CAR T Cells for Patients with MUC1+ Advanced Refractory Solid Tumor

CART-TnMUC1–01

NCT04025216

Phase 1

A Study of CART-TnMUC1 in Patients with TnMUC1-Positive Advanced Cancers

MUC1 Peptide-Poly-ICLC

NCT03300817

Phase 1

A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer

MUC1 peptide-poly-ICLC

NCT01720836

Phase 1/2

Vaccine Therapy in Treating Patients with Stage I-III Non-Small Cell Lung Cancer